Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors

Amol M Vibhute1, Hide-Nori Tanaka1, Sushil K Mishra2

  • 1Institute for Glyco-core Research (iGCORE), Gifu University, Gifu 501-1193, Japan.

Abstract

Insights

Novel UDP-GlcNAc analogs with increased hydrophobicity were synthesized and tested. These compounds showed modest inhibition and selectivity for N-Acetylglucosaminyltransferase V (GnT-V), suggesting a promising strategy for cancer drug development.

Area of Science:

  • Glycobiology
  • Enzyme Inhibitor Design
  • Cancer Therapeutics

Background:

  • N-Glycan branching influences glycoprotein functions.
  • N-Acetylglucosaminyltransferase V (GnT-V) activity is linked to cancer progression.
  • Targeting GnT-V with inhibitors is a potential cancer treatment strategy.

Purpose of the Study:

  • To design novel GnT-V inhibitors by modifying the donor substrate UDP-GlcNAc.
  • To explore the hypothesis that increased hydrophobicity of UDP-GlcNAc analogs may inhibit GnT-V.
  • To investigate the recognition mechanism of UDP-GlcNAc by GnT-V.

Main Methods:

  • Chemical synthesis of 10 UDP-GlcNAc analogs with hydrophobic modifications.
  • Development of an HPLC-based enzyme assay system to measure GnT-I-V activity.
  • Assessment of inhibitory effects and specificity of synthesized compounds on GnT-V using purified enzymes.

Main Results:

  • Several synthesized UDP-GlcNAc analogs demonstrated inhibition of GnT-V activity.
  • The compounds exhibited selectivity for GnT-V over other GnTs, indicating GnT-V's tolerance to substrate hydrophobicity.
  • Docking models provided insights into the interaction mechanisms between inhibitors and GnT-V.

Conclusions:

  • Chemical modification of the UDP-GlcNAc donor substrate is a viable strategy for developing selective GnT-V inhibitors.
  • Findings offer new perspectives on GnT inhibitor design and substrate recognition.

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.8K
Peptidoglycan Synthesis01:28

Peptidoglycan Synthesis

Structure of PeptidoglycanPeptidoglycan is a vital structural component of the bacterial cell wall, providing mechanical strength and shape to the cell. It consists of repeating units of two sugars—N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)—linked by β-1,4 glycosidic bonds. These sugar chains are cross-linked by short peptide chains, forming a mesh-like polymer that surrounds the bacterial plasma membrane.Cytoplasmic Phase – Precursor SynthesisPeptidoglycan...
584
Preparation of 1° Amines: Gabriel Synthesis01:28

Preparation of 1° Amines: Gabriel Synthesis

Direct alkylation is not a suitable method for synthesizing amines because it produces polyalkylated products. Gabriel synthesis is the most preferred method to exclusively make primary amines. The method uses phthalimide, which contains a protected form of nitrogen that participates in alkylation only once to predominantly give primary amines.
Strong bases like NaOH or KOH deprotonate the phthalimide to form the corresponding anion, which acts as a nucleophile. Further, the anion attacks an...
3.9K